Today: 2 May 2026

Canada Stock Market Today: TSX Near Record High as Mining Stocks Climb, Tech and Energy Lag – December 11, 2025

Canada Stock Market Today: TSX Near Record High as Mining Stocks Climb, Tech and Energy Lag – December 11, 2025

The S&P/TSX Composite Index hit a new intraday high near 31,546 in Toronto Thursday, up 0.3%, after closing at a record 31,490.85 on Wednesday. Gains in gold and base-metal miners offset losses in technology and energy shares. The Bank of Canada held its policy rate at 2.25% on Wednesday, following the U.S. Federal Reserve’s rate decision. Year-to-date, the TSX is up about 27%.
11 December 2025
···
Procter & Gamble (PG) Stock Outlook: Dividend King Near Two‑Year Lows as Wall Street Weighs Tariffs, Jobs Cuts and 2026 Growth

Procter & Gamble (PG) Stock Outlook: Dividend King Near Two‑Year Lows as Wall Street Weighs Tariffs, Jobs Cuts and 2026 Growth

Procter & Gamble shares fell from about $151 on November 21, 2025, to $141 intraday December 11, hitting a two-year low near $138 on December 2. The stock is down roughly 12% over three months, despite solid earnings and another dividend hike. Short-term volatility spiked, with a 2.9% drop on December 8 and a 1.2% rebound the next session. Wall Street price targets remain about 20% above current levels.
11 December 2025
·
UnitedHealth Group (UNH) Stock Outlook After the November 21 Rebound: Can the Healthcare Giant Regain Its Swagger in 2026?

UnitedHealth Group (UNH) Stock Outlook After the November 21 Rebound: Can the Healthcare Giant Regain Its Swagger in 2026?

UnitedHealth shares climbed to $332–334 intraday on December 11, up from $319.97 on November 21, but remain down about 35% over the past year. The stock trades at a trailing P/E of 14.9×, below sector average, but a forward P/E of 19×, slightly above peers. Dividend yield stands at 2.8%, with the next payout set for December 16. DOJ probe and Medicare Advantage reset continue to weigh on outlook.
11 December 2025
·
Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals shares surged to a new 52-week high above $72 on December 11 after the FDA approved its first drug, Redemplo, for familial chylomicronemia syndrome. The stock has climbed from the low-$40s to around $70 in a month, pushing market value to $9.6 billion, up over 300% year-over-year. The company also received an FDA Breakthrough Therapy designation and launched its first Alzheimer’s trial.
11 December 2025
··
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant shares rose 9% to $25.75 Thursday after the company announced a $550 million common stock offering to fund development and possible launch of its lead drug, IMVT‑1402, for Graves’ disease. The offering priced at $21 per share, an 11% discount, and is expected to close December 12. Roivant Sciences will participate. Immunovant’s market value reached about $4 billion.
11 December 2025
····
AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie shares rebounded 2.98% to $236.28 on Nov. 21, 2025, with trading volume spiking to 7.9 million after three down days. Year-to-date, the stock is up about 22–26%, outpacing the S&P 500, but remains 7–9% below its October high. Forward P/E estimates range from 16x to 22x. Investors weigh strong Skyrizi and Rinvoq sales against Humira declines and regulatory risk.
11 December 2025
···
Coeur Mining (CDE) Stock on December 11, 2025: Palmarejo Breakthroughs, $7B New Gold Deal and What Comes Next

Coeur Mining (CDE) Stock on December 11, 2025: Palmarejo Breakthroughs, $7B New Gold Deal and What Comes Next

Coeur Mining shares traded around $16.84 on December 11, up 5% intraday, with volume over 6 million. The company announced a $7 billion all-stock deal to acquire New Gold Inc. and posted record Q3 revenue of $555 million and net income of $267 million. CDE’s market value has surged to about $10 billion after a rally from a 52-week low of $4.58 to a high near $23.61.
11 December 2025
···
Snowflake (SNOW) Stock Outlook After November 21, 2025: AI Deals, Legal Risks and Price Targets to 2030

Snowflake (SNOW) Stock Outlook After November 21, 2025: AI Deals, Legal Risks and Price Targets to 2030

Snowflake shares have fallen to around $218, down 7% since November 21 and 22% below their November 3 high. The stock dropped sharply after Q3 FY26 earnings on December 3, when strong growth was offset by weaker margin guidance. Shares remain over 50% higher year-to-date. Wall Street analysts have since raised price targets despite the recent slide.
11 December 2025
··
Linde Stock (LIN) Outlook for 2026: What 52‑Week Lows, Insider Buying and New Debt Deals Signal for Investors

Linde Stock (LIN) Outlook for 2026: What 52‑Week Lows, Insider Buying and New Debt Deals Signal for Investors

Linde shares hit a 52-week low of $387.78 in late November 2025, trading at $398.9 on December 11, below key moving averages. CEO insider buying and new analyst calls followed, along with multiple debt and credit moves. Q3 adjusted EPS rose to $4.21 on $8.6 billion revenue, but weak European volumes and cautious Q4 guidance pressured the stock. Market cap stands at about $186 billion.
11 December 2025
·
Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio shares climbed to $154 on December 11, 2025, up over 130% year-to-date, after announcing positive Phase 3 results for tinlarebant in Stargardt disease. The company’s market value reached $5–6 billion. The DRAGON trial showed tinlarebant cut lesion growth by 36% versus placebo in adolescents with STGD1. Wall Street analysts project further upside for the stock.
11 December 2025
·
Wayfair (W) Stock Nears $100 as Hedge Funds Buy and Jefferies Turns Cautious – December 11, 2025 Outlook & Forecast

Wayfair (W) Stock Nears $100 as Hedge Funds Buy and Jefferies Turns Cautious – December 11, 2025 Outlook & Forecast

Wayfair shares rose about 7% Thursday to near $100, following a volatile year that saw the stock rally over 100% year to date but fall 17% in the past month. The stock remains nearly 19% below its November high. Hedge funds, including Mane Global Capital, disclosed new stakes, while short interest hovers near 15%. Insiders have been selling as analysts remain split on the outlook.
11 December 2025
··
Unity Software (NYSE: U) Stock Outlook: Analyst Upgrades, Q3 Beat and 2026 Forecasts Fuel a High‑Beta Rally

Unity Software (NYSE: U) Stock Outlook: Analyst Upgrades, Q3 Beat and 2026 Forecasts Fuel a High‑Beta Rally

Unity Software shares traded near $51 on December 11, close to a 52-week high, valuing the company at about $22 billion. The stock has rebounded roughly 90% over the past year, outpacing the S&P 500, but remains below its 2020 IPO price. Q3 2025 revenue rose 5% to $471 million, with adjusted EPS of $0.20 and free cash flow of $151 million. GAAP net loss for the quarter was $127 million.
11 December 2025
Wells Fargo Stock (WFC) Near Record Highs: Latest News, AI Job Cuts, Buybacks and 2026 Forecast

Wells Fargo Stock (WFC) Near Record Highs: Latest News, AI Job Cuts, Buybacks and 2026 Forecast

Wells Fargo stock closed at $90.68 on December 10, 2025, near its 52-week high, after the Federal Reserve lifted its asset cap in June and the bank announced a $40 billion share buyback. Shares have gained over 26% year-to-date, outpacing peers. Technical models now rate WFC a “Strong Buy” for the next three months. Regulatory scrutiny and legal settlements remain ongoing.
11 December 2025
··
Upwork (UPWK) Stock Hits Fresh 52‑Week High: AI Partnerships, Index Inclusion and Q3 Earnings Rewire the 2026 Outlook

Upwork (UPWK) Stock Hits Fresh 52‑Week High: AI Partnerships, Index Inclusion and Q3 Earnings Rewire the 2026 Outlook

Upwork shares hit a new 52-week high of $21.39 on December 11, 2025, lifting its market cap to about $2.46 billion. The stock is up nearly 90% from its yearly low, driven by record Q3 results, new AI partnerships, and entry into the S&P SmallCap 600. Insider selling and high short interest remain. Upwork now posts positive GAAP earnings and a gross margin near 78%.
11 December 2025
····
Marvell Technology (MRVL) Stock: AI Infrastructure Star Faces Fresh Amazon and Microsoft Risks After November Rally

Marvell Technology (MRVL) Stock: AI Infrastructure Star Faces Fresh Amazon and Microsoft Risks After November Rally

Marvell Technology shares rose about 17% to $90–91 as of December 11, 2025, after reporting record earnings and announcing a multi-billion-dollar AI acquisition. The stock had closed at $77.45 on November 21, before spiking near $100 and then retreating on concerns over business with Amazon and Microsoft. Institutional investors increased holdings, while insiders bought shares around $78. Trading volume and volatility surged.
11 December 2025
···
Coca-Cola (KO) Stock Outlook December 2025: New CEO, Dividend Power and Analyst Forecasts

Coca-Cola (KO) Stock Outlook December 2025: New CEO, Dividend Power and Analyst Forecasts

Coca-Cola shares traded around $69–70 intraday on December 11, 2025, down from late-November highs above $73 but well above the 52-week low. The board named Henrique Braun as CEO effective March 31, 2026, with James Quincey moving to Executive Chairman. KO delivered an estimated 11.9% one-year return, lagging the S&P 500 but outperforming its industry.
11 December 2025
···
BitMine Immersion Technologies (BMNR) Stock: Ethereum Mega‑Treasury, Dividend Debut and 2026 Outlook After the November 21, 2025 Earnings Shock

BitMine Immersion Technologies (BMNR) Stock: Ethereum Mega‑Treasury, Dividend Debut and 2026 Outlook After the November 21, 2025 Earnings Shock

BitMine Immersion Technologies reported $328.2 million net income for fiscal 2025 and announced its first annual dividend on November 21. The company ramped Ethereum holdings above 3.86 million tokens but faced $3.7 billion in unrealized losses after ETH’s sharp drop. Shares saw extreme volatility and diverging analyst forecasts. BitMine launched a new Ethereum staking roadmap and aims to control 5% of ETH supply.
11 December 2025
···
1 … 1,248 1,249 1,250 1,251 1,252 … 1,889

Stock Market Today

  • Chugai Pharmaceutical Reports Strong Q1 Earnings, Introduces Trust-Based Stock Plan
    May 2, 2026, 1:28 AM EDT. Chugai Pharmaceutical (TSE:4519) posted robust first-quarter 2026 earnings, with sales of ¥291.6 billion, revenue of ¥321.7 billion, and net income of ¥115.4 billion surpassing prior year levels. The company's board unveiled a trust-based stock compensation system to better align management incentives with performance amid rising R&D expenses and strategic collaborations. Despite near-term strength, investors face risks from patent expiries, biosimilars, and National Health Insurance (NHI) price revisions that could pressure margins. Forecasts project ¥1.38 trillion revenue and ¥517 billion earnings by 2028, implying modest growth. Analysts remain divided, with some optimistic on AI-driven pipeline advancements, while others caution on pricing and competitive threats. The governance changes highlight an evolving incentive model as Chugai navigates opportunities and challenges in biologics and Roche partnership dynamics.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 02.05.2026

2 May 2026
LIVEMarkets rolling coverageStarted: May 2, 2026, 12:00 AM EDTUpdated: May 2, 2026, 1:38 AM EDT Chugai Pharmaceutical Reports Strong Q1 Earnings, Introduces Trust-Based Stock Plan May 2, 2026, 1:28 AM EDT. Chugai Pharmaceutical (TSE:4519) posted robust first-quarter 2026 earnings, with sales of ¥291.6 billion, revenue of ¥321.7 billion, and net income of ¥115.4 billion surpassing prior year levels. The company's board unveiled a trust-based stock compensation system to better align management incentives with performance amid rising R&D expenses and strategic collaborations. Despite near-term strength, investors face risks from patent expiries, biosimilars, and National Health Insurance (NHI) price revisions that could
US Stock Market Today After Hours: Nasdaq Tops 25,000 As S&P 500 Hits Record High

US Stock Market Today After Hours: Nasdaq Tops 25,000 As S&P 500 Hits Record High

2 May 2026
Nasdaq 100 futures climbed 0.68% and S&P 500 futures edged up 0.06% in early after-hours trading Friday, while Dow futures slipped 0.48%. The S&P 500 and Nasdaq closed at record highs, driven by first-quarter S&P 500 profit growth of 27.8%, according to LSEG. Oil prices, inflation signals, and upcoming jobs data remain in focus. GameStop shares rose 4% after reports it was preparing an offer for eBay.
McDonald’s Corporation Stock Slides Before Earnings as Its Big Drink Bet Comes Due

McDonald’s Corporation Stock Slides Before Earnings as Its Big Drink Bet Comes Due

2 May 2026
McDonald’s shares fell 2.37% to $286.64 on Friday, underperforming rivals ahead of its May 7 earnings report and a U.S. launch of six new McCafé specialty drinks. The company will begin selling the drinks nationwide on May 6, adding beverage specialist roles at 14,000 restaurants. Investors are watching whether the new drinks and value offers can boost traffic without slowing service or hurting margins.
Go toTop